Clinical trial reveals risky clot busters do not benefit most patients suffering from deep vein thrombosis

December 11, 2017, McGill University

A clinical trial almost 10 years in the making has revealed that risky, but powerful, clot busting drugs and medical devices do not improve outcomes for patients experiencing deep vein thrombosis (DVT), nor do they prevent the development of post-thrombotic syndrome (PTS) when compared with conventional blood thinning medications. The results of the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) study are published in the New England Journal of Medicine.

Approximately 50,000 Canadians are diagnosed every year with DVT, and up to 40% of these will go on to develop PTS, a complication that can leave them with chronic limb pain and swelling that can impede their daily activities. It had been hypothesized that the inability of blood thinners to remove the acute blood might be overcome by employing clot busters as an adjuvant therapy.

"We found no particular advantage to employing clot busters and do not believe they should be applied to the majority of patients who present with acute DVT. Moreover, clot busters are associated with a higher risk for dangerous bleeding," said Dr. Susan Kahn of the Centre for Clinical Epidemiology at the Lady Davis Institute of the Jewish General Hospital. She is an internationally recognized expert in the treatment of DVT and Director of the Hospital's Centre of Excellence in Thrombosis and Anticoagulation Care (CETAC). Dr. Kahn, who is also a professor of medicine at McGill University in the department of Epidemiology, Biostatistics and Occupational Health, chaired the Clinical Outcomes Committee for the ATTRACT Trial and is a member of the trial's steering committee.

The ATTRACT study – a randomized controlled trial primarily funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) – was designed to determine whether performing the procedure as part of initial treatment for patients when they are first diagnosed with DVT would reduce the number of people who later develop the syndrome. It was initiated in 2008, following a call to action on DVT and, specifically, for research into the benefits and risks of removing clots issued by the then-Acting Surgeon General of the United States, Dr. Steven K. Galson.

The study involved 692 patients at 56 clinical sites, randomly assigned to receive blood thinners alone or blood thinners and the procedure. Each patient was followed for two years. Complications developed in 157 of 336 (47%) of people who underwent the procedure and 171 of 355 (48%) of people who did not, a difference that is not statistically significant. The procedure did reduce the severity of PTS, easing patients' long-term symptoms. About 24% of people on thinners alone experienced moderate to severe pain and swelling, but only 18% of people who were treated with and clot busters did so.

The researchers noted a worrisome increase in the number of people who developed major bleeding after undergoing the procedure. While the numbers were small – one patient (0.3%) on standard treatment experienced a bleed, compared with six (1.7%) among those who received – the potential for catastrophic bleeding is why these drugs are usually reserved for life-threatening emergencies such as heart attacks and strokes. Furthermore, the is expensive and often requires a hospital stay.

"There is a suggestion that this intervention is effective in reducing more severe cases of PTS, but this calls for further study," said Dr. Kahn. "The practice at the JGH has been to offer such treatments only in rare cases of very extensive DVT of the leg and, on occasion, of the arm, where the swelling is so significant that we fear the onset of limb gangrene. We are confident that we have been using these therapies properly and will continue with our existing protocols. This study's results also highlight that new approaches to preventing PTS are needed."

Explore further: Clot-busting drugs not recommended for most patients with blood clots

More information: Suresh Vedantham et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis, New England Journal of Medicine (2017). DOI: 10.1056/NEJMoa1615066

Related Stories

Clot-busting drugs not recommended for most patients with blood clots

December 6, 2017
Not all patients with blood clots in their legs - a condition known as deep vein thrombosis - need to receive powerful but risky clot-busting drugs, according to results of a large-scale, multicenter clinical trial.

Over 10,000 Canadian women per year can stop taking blood thinners for unexplained clots

April 4, 2017
A Canadian-led research group has developed and validated a rule that could let half of women with unexplained vein blood clots stop taking blood thinners for life. These findings were published in The BMJ.

Serious complication of post-thrombotic syndrome often causes lengthy disability

March 4, 2014
Deep vein thrombosis (DVT) often brings with it the risk of post-thrombotic syndrome (PTS), an under-recognized but serious complication that often causes long-term disability for patients. During March's DVT Awareness Month, ...

Sex-based differences in utilization and outcomes for catheter-directed thrombolysis

March 20, 2017
Deep vein thrombosis (DVT) is a serious condition that occurs when a blood clot forms in a vein, often in the deep veins of the legs, thigh or pelvis. Those clots can break loose, travel to the lungs and block blood flow, ...

'Clot-busting' drugs reduce deaths from pulmonary embolism by nearly half

June 17, 2014
Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics ...

Recommended for you

The molecular mechanism underlying hypertrophic cardiomyopathy

August 20, 2018
A study led by Stanford Medicine researchers shows why so many mutations associated with hypertrophic cardiomyopathy, a heart disorder, alter a key constituent of muscle cells in a way that makes it work overtime.

Chagas disease, caused by a parasite, has spread outside of Latin America and carries a high risk of heart disease

August 20, 2018
Chagas disease, caused by infection with a parasite called Trypanosoma cruzi (T cruzi), causes chronic heart disease in about one third of those infected. Over the past 40 years, Chagas disease has spread to areas where it ...

Gout could increase heart disease risk

August 17, 2018
Having a type of inflammatory arthritis called gout may worsen heart-related outcomes for people being treated for coronary artery disease, according to new research.

Stroke patients treated at a teaching hospital are less likely to be readmitted

August 17, 2018
Stroke patients appear to receive better care at teaching hospitals with less of a chance of landing back in a hospital during the early stages of recovery, according to new research from The University of Texas Health Science ...

Cardiovascular disease related to type 2 diabetes can be reduced significantly

August 16, 2018
Properly composed treatment and refraining from cigarette consumption can significantly reduce the risk of cardiovascular disease resulting from type 2 diabetes, according to a study published in the New England Journal of ...

Genomic autopsy can help solve unexplained cardiac death

August 15, 2018
Molecular autopsies can reveal genetic risk factors in young people who unexpectedly die, but proper interpretation of the results can be challenging, according to a recent study published in Circulation.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.